Our Pricing

Understanding Mounjaro 5 mg: Your Complete UK Guide to the Starting Dose

Mounjaro 5 mg represents the initial maintenance dose in the tirzepatide weight loss treatment programme, prescribed after completing the 2.5 mg titration phase. As a UK-registered pharmacy with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing clinical care, we've supported thousands of patients beginning their Mounjaro 5 mg journey. This guide explains dosing protocols, expected outcomes, and how to access genuine tirzepatide injections at competitive UK pricing.

What Is Mounjaro 5 mg and How Does It Work?

Mounjaro 5 mg contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. This starting maintenance dose follows four weeks of 2.5 mg titration, allowing your body to adapt gradually to the medication's effects on appetite regulation and glucose metabolism.

The dual-agonist mechanism sets tirzepatide apart from single-pathway GLP-1 medications. By activating both GIP and GLP-1 receptors, Mounjaro 5 mg enhances insulin secretion when blood glucose rises, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways [2]. Clinical trial participants on the 5 mg dose experienced significant weight reduction compared to placebo, though higher doses (10 mg and 15 mg) demonstrated greater efficacy in the SURMOUNT-1 trial [1].

Each Mounjaro 5 mg KwikPen delivers a single subcutaneous injection, administered once weekly on the same day each week. The pre-filled pen design eliminates dosing errors and simplifies self-administration. Patients typically remain on the 5 mg dose for at least four weeks before their prescriber evaluates whether dose escalation to 7.5 mg is clinically appropriate, based on weight loss progress and tolerability.

Mounjaro 5 mg Dosing Schedule and Titration Protocol

The Mounjaro 5 mg dose follows a structured titration protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. All patients begin with 2.5 mg once weekly for four weeks, then escalate to 5 mg for a minimum of four weeks [3]. This gradual approach allows the digestive system to adapt to delayed gastric emptying, significantly reducing nausea and vomiting incidence compared to rapid dose escalation.

Your UK prescriber will assess your response to Mounjaro 5 mg at the four-week mark, evaluating weight loss trajectory, side effect profile, and metabolic improvements. If you've tolerated the dose well and additional weight loss is clinically beneficial, escalation to 7.5 mg may be recommended. The maximum licensed dose is 15 mg once weekly, reached through incremental increases every four weeks [3].

Consistency in injection timing optimises tirzepatide's pharmacokinetics. Choose a day that fits your routine—many patients prefer Sunday evening or Monday morning to maintain weekend flexibility. If you miss a dose and fewer than four days have passed, inject as soon as possible. If more than four days have elapsed, skip that dose and resume your regular schedule. Never double-dose to compensate for a missed injection.

When to Stay on Mounjaro 5 mg Versus Escalating Dose

Some patients achieve their weight loss goals on Mounjaro 5 mg without requiring higher doses. If you're experiencing consistent weekly weight reduction (typically 0.5-1 kg per week), minimal side effects, and improved metabolic markers, your prescriber may recommend maintaining the 5 mg dose rather than escalating. This approach reduces medication costs whilst still delivering clinically meaningful outcomes.

Conversely, if weight loss plateaus after eight weeks on 5 mg, or if you require additional glycaemic control for type 2 diabetes management, dose escalation becomes appropriate. The SURMOUNT-1 trial demonstrated that participants on 10 mg and 15 mg doses achieved greater mean weight reductions than those on 5 mg, though all doses significantly outperformed placebo [1]. Your prescriber balances efficacy goals against tolerability and individual response patterns.

Expected Weight Loss Results with Mounjaro 5 mg

In the SURMOUNT-1 clinical trial, participants receiving Mounjaro 5 mg achieved an average weight reduction of approximately 15% from baseline over 72 weeks, compared to 3.1% with placebo [1]. However, individual results vary considerably based on adherence, dietary modifications, physical activity levels, and metabolic factors. Most patients notice appetite suppression within the first week of starting the 5 mg dose, with measurable weight loss typically evident by week four.

The initial four weeks on Mounjaro 5 mg often yield the most dramatic changes, as your body adjusts to reduced caloric intake and altered hunger signalling. Average weekly weight loss during this phase ranges from 0.5 to 1.5 kg, though some patients experience more gradual reductions. Sustainable weight management requires concurrent lifestyle modifications—clinical trials combined tirzepatide with reduced-calorie diets and increased physical activity [1].

It's essential to maintain realistic expectations regarding Mounjaro 5 mg outcomes. Whilst some patients achieve significant weight loss on this dose alone, others require escalation to 7.5 mg, 10 mg, or 15 mg to reach their goals. Your UK prescriber will monitor progress through regular follow-ups, adjusting your treatment plan based on response patterns. Weight loss typically continues for 60-72 weeks before stabilising, at which point maintenance strategies become paramount.

Mounjaro 5 mg Side Effects and Management Strategies

Gastrointestinal side effects represent the most common adverse reactions to Mounjaro 5 mg, affecting approximately 20-30% of patients during the initial weeks [2]. Nausea, diarrhoea, constipation, and reduced appetite typically peak during the first two weeks on a new dose, then gradually subside as your body adapts. These effects result from delayed gastric emptying and altered gut hormone signalling—pharmacological mechanisms that also contribute to weight loss efficacy.

To minimise nausea on Mounjaro 5 mg, eat smaller, more frequent meals rather than large portions. Avoid high-fat, greasy, or heavily spiced foods that exacerbate gastric discomfort. Stay well-hydrated, particularly if experiencing diarrhoea, and consider ginger tea or plain crackers when nausea strikes. Most patients find these symptoms resolve within 2-4 weeks without requiring antiemetic medications.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia (primarily in patients taking concurrent diabetes medications). Contact your prescriber immediately if you experience severe abdominal pain radiating to the back, persistent vomiting, or signs of low blood sugar such as tremors, confusion, or rapid heartbeat. Mounjaro 5 mg is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

Managing Injection Site Reactions with Mounjaro 5 mg

Mild injection site reactions—redness, itching, or small lumps—occur in approximately 5% of Mounjaro 5 mg users [2]. Rotate injection sites weekly between your abdomen, thigh, and upper arm to prevent tissue irritation. Avoid injecting into areas with scars, bruises, or active skin conditions. Allow the pen to reach room temperature before injecting, as cold medication increases discomfort.

If you develop persistent injection site reactions, ensure you're using proper technique: pinch the skin, insert the needle at 90 degrees, and hold for 10 seconds after pressing the button. Never reuse needles or share pens. Most reactions resolve within 24-48 hours without intervention. Persistent or worsening symptoms warrant consultation with your prescriber to rule out allergic reactions or infection.

How to Buy Mounjaro 5 mg Online in the UK Safely

Purchasing Mounjaro 5 mg requires a valid prescription from a UK-registered prescriber, as tirzepatide is a prescription-only medicine regulated by the MHRA. At Cured Pharmacy (GPhC 9012511), our clinical assessment takes under three minutes and is reviewed by qualified prescribers who evaluate your medical history, current medications, and weight loss goals. This ensures tirzepatide is clinically appropriate and safe for your individual circumstances.

Beware of websites offering Mounjaro 5 mg without prescriptions or clinical oversight—these sources often supply counterfeit or unregulated products that pose serious health risks. Genuine tirzepatide must be stored at 2-8°C until first use, with strict cold-chain logistics throughout distribution. Cured Pharmacy sources all Mounjaro stock directly from licensed UK wholesalers, guaranteeing authenticity and proper storage conditions.

Our transparent pricing model displays costs upfront: Mounjaro 5 mg starts from £159.00, with new patients saving £159.00 using code Weightlossnew at checkout. This includes the medication, clinical consultation, and discreet next-day delivery. Unlike some providers who add hidden consultation fees or subscription charges, our pricing remains clear and competitive across all weight loss treatments.

Mounjaro 5 mg Versus Other Weight Loss Injections

When comparing Mounjaro 5 mg to alternative weight loss injections, efficacy data and mechanism of action differentiate treatment options. Wegovy (semaglutide) acts solely on GLP-1 receptors, whilst tirzepatide's dual GIP/GLP-1 activity demonstrated superior weight loss in head-to-head trials. The SURMOUNT-2 study showed tirzepatide users achieved greater mean weight reductions than semaglutide users at comparable doses [4].

Saxenda (liraglutide) represents an earlier-generation GLP-1 agonist requiring daily injections, compared to Mounjaro 5 mg's once-weekly administration. Clinical trials indicate tirzepatide produces greater weight loss than liraglutide, though Saxenda remains effective for patients who prefer daily dosing or have contraindications to tirzepatide [4]. Cost considerations also influence treatment selection—Saxenda typically costs less per month than Mounjaro, though requires more frequent injections.

Your prescriber considers multiple factors when recommending Mounjaro 5 mg versus alternatives: your weight loss goals, previous medication responses, injection frequency preferences, budget constraints, and comorbid conditions. Some patients achieve optimal results with Mounjaro 5 mg, whilst others respond better to semaglutide or liraglutide. Regular follow-ups allow treatment adjustments based on real-world outcomes rather than trial averages.

Switching to Mounjaro 5 mg from Other GLP-1 Medications

Patients transitioning to Mounjaro 5 mg from other GLP-1 agonists should follow specific protocols to ensure safe conversion. If switching from Wegovy or Ozempic (semaglutide), your prescriber will typically start you on Mounjaro 2.5 mg for four weeks before escalating to 5 mg, even if you were on higher semaglutide doses. This titration minimises gastrointestinal side effects during the transition period.

When converting from Saxenda (liraglutide), discontinue the daily injections and begin Mounjaro 2.5 mg within 24 hours. Do not overlap medications, as this increases hypoglycaemia and gastrointestinal side effect risks. Your prescriber will monitor your response closely during the first month, adjusting the transition timeline if tolerability issues arise. Most patients successfully switch to Mounjaro 5 mg without significant complications when following proper protocols.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.
3. Electronic Medicines Compendium. (2023). Mounjaro 5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency.
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of tirzepatide versus semaglutide in adults with overweight or obesity: The SURMOUNT-2 trial. Nature Medicine, 29(11), 2909-2919.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.